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Abstract
Background: Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1).
Skin toxicity most commonly includes a maculopapular erythematous rash and pruritus. Rarely life threatening
complications such as Steven’s Johnson syndrome or toxic epidermal necrolysis may occur.
Case presentation: Here we report the uncommon event of a drug-induced transient acantholytic dermatosis
(Grover’s disease) in a 73-year-old Caucasian male treated with ipilimumab for metastatic melanoma. Five weeks
after initiation of therapy, the patient developed a widespread polymorphic papulovesicular dermatosis on the
trunk and proximal extremities with intense pruritus. Skin biopsy showed acantholytic dyskeratosis with interface
dermatitis consistent with a Grover’s-like drug eruption.
Conclusions: These findings should raise awareness for uncommon immune-related dermatological toxicities of
immunomodulatory antibodies targeting the CTLA-4 signaling axis. We recommend biopsies of unexpected skin
lesions to rapidly identify dermatological adverse events of immune checkpoint inhibitors.
Keywords: Melanoma, Immunotherapy, Immune checkpoint inhibitors, Autoimmunity, Ipilimumab, Grover’s disease,
Transient acantholytic dermatosis, Drug eruption
Background
Recent years have witnessed a breakthrough in the therapy
of advanced melanoma. Ipilimumab, a fully humanized
monoclonal IgG1 antibody targeting the immunological
checkpoint surface molecule cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4), has been shown to im-
prove the overall survival of patients with metastatic
melanoma in clinical trials [1–3]. Dermatologic toxicity
is a common drug-related adverse event associated with
this treatment. Approximately half of the patients
treated with ipilimumab will experience rash and/or
pruritus [4]. For most patients, dermatologic toxicity is
the earliest detectable immune-related adverse event,
with average onset at 3.6 weeks after the initiation of
immunotherapy [5, 6]. Typical macroscopic findings
include polymorphic, reticular, maculopapular, faintly
erythematous rashes on the trunk or extremities and
vitiligo [7]. Histologically, superficial and deep perivascular
lymphocytic infiltrates consisting of CD4+ and CD8+
effector T-cells with a concomitant infiltrate of CD4+
Foxp3+ regulatory T-cells have been observed indicating
a partial breach of tolerance to normal skin [8].
Grover’s disease, also known as transient acantholytic
dermatosis, generally occurs among older white males
(male-to-female ratio 2.4:1, mean age at diagnosis 61 years)
with an incidence of 0.8 % in the hospital setting [9].
While generally accepted to be a benign, self-limited dis-
order, it can be persistent and difficult to manage; hence,
the description of transient is misleading [9]. It usually
occurs as a pruritic, polymorphic papulovesicular rash of
the upper trunk and proximal extremities. Histologically,
small, circumscribed foci of suprabasal acantholysis are
* Correspondence: kirsten.mertz@ksbl.ch
1Cantonal Hospital Baselland, Institute of Pathology, Mühlemattstrasse 11,
CH-4410 Liestal, Switzerland
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Koelzer et al. Journal for ImmunoTherapy of Cancer  (2016) 4:47 
DOI 10.1186/s40425-016-0151-z
found. The presence of scattered dyskeratotic cells, spon-
giosis and the level of acantholysis has been used to dif-
ferentiate a Darier-like, spongiotic, Hailey-Hailey-like,
Pemphigus-foliaceus-like, Pemphigus-vulgaris-like and
mixed pattern [9]. An accompanying lymphohistiocytic
interface dermatitis with perivascular infiltrates is
common [9]. A clinically significant association between
Grover’s disease and cancer, including acute leukemia, has
been discovered [10, 11]. The pruritus and papulovesicular
rash can be exacerbated by exercise, heat, sweating and
ultraviolet light exposure. Although most studies report
no association with specific drugs, individual authors have
implicated interleukin 4 and D-penicillamine as disease
triggers [12, 13]. However, although recognized as a com-
mon condition, the pathogenesis of Grover’s disease still
remains unknown. Since it is frequently associated with
other neoplastic and non-neoplastic conditions, its occur-
rence can be an early indicator of an underlying disease.
Case presentation
A 73-year-old Caucasian male was evaluated for a tran-
sient ischemic attack (TIA) in May 2015. Computed
tomography (CT) imaging incidentally showed multiple
poorly circumscribed pulmonary nodules with a max-
imum diameter of 1.7 cm restricted to the upper lobe
of the right lung, suggestive of malignancy. A positron
emission tomography–computed tomography (PET/CT)
showed intense uptake of 2-deoxy-2-(18 F)fluoro-D-
glucose (18 F-FDG) in the pulmonary nodules. A diag-
nostic thoracoscopy with wedge resection of one nodule
was carried out. Frozen section revealed a poorly diffe-
rentiated neoplasia with epithelioid and spindle cell
morphology of unclear etiology. Based on the differential
diagnosis of a primary tumor of the lung, a lobectomy of
the right upper lobe and mediastinal lymphadenectomy
was performed.
The formalin fixed and paraffin embedded material
showed focal areas of pigment accumulation, and the
tumor cells stained positive for S100, melan-A and
HMB-45, consistent with malignant melanoma. Molecu-
lar testing revealed no BRAF, NRAS or c-KIT mutations.
A dermatological consultation did not show an indica-
tion of a primary cutaneous melanoma. The patient was
diagnosed with stage IV melanoma of unknown primary.
Subsequent magnetic resonance and PET/CT imaging 2
months after lobectomy revealed a hepatic metastasis in
segment II and progression of the pulmonary lesions.
The patient was treated with four cycles of ipilimumab
(Yervoy®), administered at a dose of 3 mg/kg body weight
every 3 weeks (Fig. 1).
Three weeks after the second infusion of ipilimumab,
the patient presented with a sudden eruption of a papu-
lovesicular polymorphic exanthema on the trunk and
proximal extremities, associated with a generalized and
severe pruritus. On physical examination, he had mul-
tiple erythematous, 2- to 7-mm scaly papules and fragile
vesicles on his chest, abdomen, back, shoulders and
proximal limbs, which quickly formed crusts and kera-
totic erosions (Fig. 2a). A skin biopsy was performed.
The predominant histological pattern was suprabasal
acantholysis of keratinocytes with scattered dyskeratotic
cells at various levels of the epidermis, suggestive of a
Darier-like form of Grover’s disease. In addition, histo-
logical examination of the skin biopsy revealed a mild
interface dermatitis and perivascular, lymphohistiocytic
infiltrates with scattered eosinophils in the superficial
dermis (Fig. 2b). Immunohistochemically, the infiltrate
was composed of CD4+ and CD8+ T-cells with frequent
but weak PD-1 expression and intermingled CD68+
macrophages (data not shown). No epidermal infiltrates
were noted. Direct immunofluorescence studies for im-
mune complex deposition were negative.
The pruritus and the rash were assessed as grade 2
toxicity, and the treatment with ipilimumab was contin-
ued according to the schedule. Of note, the patient had
no recent medical history of fever, infectious conditions
or abundant sweating. He also had no history of auto-
immune diseases or a previous episode of Grover’s disease.
The acantholytic rash and the itching were responsive to
topical treatment with hydrocortisone butyrate 0.1 % lo-
tion with menthol 1 %. However, the skin lesions persisted
for more than 2 months after the end of the ipilimumab
treatment. No other iplilimumab-related adverse events
were noted in this patient.
After 4 cycles of treatment of ipilimumab the patient
showed stable disease (RECIST 1.1 [14]) based on CT
Fig. 1 Time axis. Line graph illustrating disease progression and therapeutic intervention from primary diagnosis in May 2015 to April 2016
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examination of the thorax and abdomen, and symptoma-
tically experienced relief of his disease-related chronic
cough, dyspnea and fatigue. In March 2016, 4 months
after termination of therapy, the patient presented with
stable disease on CT-scan and all skin lesions had healed.
At the end of April 2016, there was appearance of new
brain metastasis with epileptic seizures and aphasia. Treat-
ment with full brain radiation and steroid infusions was
initiated. There was no re-appearance of the skin lesions.
Discussion
The modulation of signaling via coinhibitory or costimu-
latory receptors expressed on T-cells is a potent way to
amplify antitumor immune responses. This approach
has been exploited successfully for the generation of
monoclonal antibodies against the immune checkpoints
CTLA-4 and PD-1/PD-L1. Because checkpoint blockade
does not just enhance tumor-specific immune responses,
autoimmunity can occur as an adverse event. Inhibition
of the PD-1 and CTLA-4 feedback loop commonly in-
duces a dysregulation of the immune system associated
with severe and even fatal immune-related adverse
events due to T-cell activation and proliferation. While
any organ system may be involved, cutaneous side effects
are frequent. Here we report the case of a 73-year-old
male patient with metastatic melanoma treated with
ipilimumab who developed a widespread pruritic eruption
with histopathologic findings of acantholytic dyskeratosis,
consistent with a Grover’s-like drug eruption.
Grover’s-like drug eruptions have been previously as-
sociated with the use of BRAF inhibitors such as
vemurafenib [15] and dabrafenib [16]. The etiology of
this finding is unknown, but given its relative frequency
in patients treated with BRAF inhibitors, paradoxical
activation of the MAPK pathway might play a role. Most
of the patients who developed drug-induced cutaneous
reactions under BRAF inhibitors responded to topical
emollients or corticosteroids, with only a few severe
cases requiring oral corticosteroids or retinoids [17].
A Grover’s-like drug eruption under immune-
checkpoint inhibitor treatment has been previously re-
ported in only one single patient who received ipilimu-
mab for stage IV melanoma [18]. The here presented
case differs from this previous report and extends the
characterization of ipilimumab-induced acantholytic
dermatosis in several aspects: First, no characterization
of cutaneous immune infiltrates in ipilimumab-induced
Grover’s disease was previously attempted. Here we
show a co-existence of typical features of acantholytic
dermatosis with low-grade interface dermatitis and
perivascular lymphocytic infiltrates composed primarily
of CD4+ and CD8+ T-cells. Increased dermal and peri-
vascular lymphocytic infiltrates have been previously
reported as a feature of ipilimumab-induced rash and
may indicate partial breach of tolerance to normal skin
[8]. Increased superficial perivascular infiltrates are also
frequently identified in Grover’s disease [9]. Taken to-
gether, these coincidental findings may indicate a
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Fig. 2 Skin findings after the second course of ipilimumab treatment. a) Clinical presentation. Overview image showing the diffuse eruption of
a papulovesicular rash on the patient’s trunk (left). Detail image showing lesions of different stages ranging from early erythematous papules to
crusty and scaly erosions (right). b Histopathological findings on skin biopsy (Hematoxylin-eosin stain). Overview image demonstrating circumscript
acantholytic dyskeratosis and mild interface dermatitis with perivascular accentuation as an accompanying feature (left). Detail image showing
Darier-like features with acatholytic and dyskeratotic keratinocytes present at all levels of the epidermis (right). Scale bars are indicated.
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potential pathogenic involvement of the T-cell response
in the development of Grover’s disease and merit fur-
ther investigation.
Second, the exanthema in our patient was very exten-
sive, affecting the patient’s entire trunk and proximal
extremities. The size of the skin lesions varied consider-
ably, and the rash and pruritus of the patient did not
resolve immediately and completely after ipilimumab
disruption, but only with a delay of 2 months. Our case
is similar to the previously reported case with respect
to the absence of other medications and other causes
for abundant sweating, which could represent other
causative triggers for the patient’s skin manifestation.
Similarities are also found in an association of the
Grover’s-like drug eruption with therapeutic response to
immune-checkpoint inhibitor therapy. Further analyses
are required to clarify whether drug-induced Grover’s
disease may represent a form of on-target dermatologic
toxicity that is linked to clinical efficacy.
Conclusions
Patients treated with immune checkpoint inhibitors –
the CTLA-4 antibody ipilimumab or anti-PD1/-PD-L1
inhibitors – require continuous dermatologic monitoring
throughout their treatment. A timely classification of
dermatologic toxicity into harmless or life-threatening
events is needed to consider interruption of immuno-
therapy and introduction of immunosuppressive drugs.
Ipilimumab-induced Grover’s disease is a rare complica-
tion, histologically characterized by acantholytic dyskera-
tosis with mild interface dermatitis and perivascular
lymphocytic infiltration. Based on the presently available
evidence, this immune-related adverse event follows a
benign course, responds well to symptomatic treatment
and does not require interruption of immune checkpoint
inhibitor therapy.
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